BEAM — Beam Therapeutics Share Price
0.000.00%
Last trade - 00:00HealthcareSpeculativeLarge CapNeutral
- $4.62bn
- $3.46bn
- $51.84m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.78 | ||
| Price to Tang. Book | 5.78 | ||
| Price to Free Cashflow | 37.57 | ||
| Price to Sales | 60.09 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -24.15% | ||
| Return on Equity | -34.7% | ||
| Operating Margin | -378.74% | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 0.02 | 0.02 | 51.84 | 42.81 | 32.15 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
12345678910
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Beam Therapeutics Inc. is a biotechnology company. The Company is focused on developing precision genetic medicines based on its base editing technology to provide life-long cures to patients suffering from diseases. Its base editing technology enables a new class of precision genetic medicines that targets a single base in the genome without making a double-stranded break in the deoxyribonucleic acid (DNA). The Company’s base editing technology of therapeutic applications pursue a suite of both clinically validated and delivery modalities, depending on tissue type, which includes electroporation for delivery to blood cells and immune cells ex vivo; lipid nanoparticles (LNPs), for non-viral in vivo delivery to the liver and potentially other organs in the future, and adeno-associated viral vectors (AAV), for in vivo viral delivery to the eye and potentially other organs. The Company has four development candidates, which include BEAM-101, BEAM-102, BEAM-201 and BEAM-301.
Directors
- Giuseppe Ciaramella PRE (52)
- John Evans CEO (44)
- Terry-Ann Burrell CFO (42)
- John Maraganore DRC
- Kristina Burow IND (47)
- Graham Cooper IND (51)
- Mark Fishman IND (70)
- Carole Ho IND (48)
- Kathleen Walsh IND (65)
- Last Annual
- December 31st, 2021
- Last Interim
- June 30th, 2022
- Incorporated
- January 25th, 2017
- Public Since
- January 1st, 1970
- No. of Shareholders
- 38
- No. of Employees
- 341
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 70,312,114
- Address
- 26 Landsdowne St, CAMBRIDGE, 02139-4216
- Web
- https://beamtx.com/
- Phone
- +1 8573278775
- Auditors
- Deloitte & Touche LLP
Upcoming Events for BEAM
Similar to BEAM
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Beam Therapeutics share price?
As of Today at 19:03 UTC, shares in Beam Therapeutics are trading at $65.73. This share price information is delayed by 15 minutes.
How has the Beam Therapeutics share price performed this year?
Shares in Beam Therapeutics last closed at $65.73 and the price had moved by -36.97% over the past 365 days. In terms of relative price strength the Beam Therapeutics share price has underperformed the S&P500 Index by -33.41% over the past year.
What are the analyst and broker recommendations for Beam Therapeutics?
The overall consensus recommendation for Beam Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Beam Therapeutics dividend yield?
Beam Therapeutics does not currently pay a dividend.
Does Beam Therapeutics pay a dividend?
Beam Therapeutics does not currently pay a dividend.
When does Beam Therapeutics next pay dividends?
Beam Therapeutics does not currently pay a dividend.
How do I buy Beam Therapeutics shares?
To buy shares in Beam Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Beam Therapeutics?
As of the previous close price of $65.73, shares in Beam Therapeutics had a market capitalisation of $4.62bn.
Where are Beam Therapeutics shares listed?
Here are the trading details for Beam Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: BEAM
What kind of share is Beam Therapeutics?
Based on an overall assessment of its quality, value and momentum Beam Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Beam Therapeutics share price forecast for 2022?
The analyst consensus target price for shares in Beam Therapeutics is $92.27. That is 40.38% above the last closing price of $65.73.
Analysts covering Beam Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$4.52 for the next financial year.
What is the trend in the Beam Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Beam Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +8.71%.
As of the last closing price of $65.73, shares in Beam Therapeutics were trading +7.43% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Beam Therapeutics PE Ratio?
The Beam Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $65.73.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Beam Therapeutics?
Beam Therapeutics' management team is headed by:
- Giuseppe Ciaramella - PRE
- John Evans - CEO
- Terry-Ann Burrell - CFO
- John Maraganore - DRC
- Kristina Burow - IND
- Graham Cooper - IND
- Mark Fishman - IND
- Carole Ho - IND
- Kathleen Walsh - IND